

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5875773

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TRANSSINE TECHNOLOGIES CO. LTD.	10/25/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	TRANSINE THERAPEUTICS LIMITED
<b>Street Address:</b>	1 MIDDLE DRIFT
<b>City:</b>	ROYSTON
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	SG8 5BU
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14008186
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(212) 765-5070
<b>Email:</b>	apsi@fr.com
<b>Correspondent Name:</b>	SAMUEL BORODACH
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.
<b>Address Line 2:</b>	P.O.BOX 1022
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022
<b>ATTORNEY DOCKET NUMBER:</b>	30829-0002US1
<b>NAME OF SUBMITTER:</b>	ROSELYNN FIGUEROA
<b>SIGNATURE:</b>	/Roselynn Figueroa/
<b>DATE SIGNED:</b>	12/18/2019
<b>Total Attachments: 3</b>	
source=US_ASSIGNMENT#page1.tif	
source=US_ASSIGNMENT#page2.tif	
source=US_ASSIGNMENT#page3.tif	

**ASSIGNMENT OF PATENT ASSETS**

This Assignment of Patent Assets ("*Assignment*") is made and entered into on this 25<sup>th</sup> day of October 2019, by and between:

**TransSINE Technologies Co. Ltd.**, a company having a place of business at 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045 Japan ("**ASSIGNOR**"); and

**TransSINE Therapeutics Limited**, a company having a place of business at 1 Middle Drift, Royston, United Kingdom, SG8 5BU ("**ASSIGNEE**").

**WHEREAS**, ASSIGNOR has agreed to assign and transfer to ASSIGNEE all its right, title and interest in and to the Assigned Patent Assets (as defined below).

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR, intending to be legally bound, and upon the terms set forth herein, agrees as follows:

ASSIGNOR does hereby irrevocably assign, sell, transfer and set over to ASSIGNEE its entire right, title and interest in, to and under the U.S. patent(s) and patent application(s) set forth on **Attachment A** attached hereto, including any and all letters patents issuing from any continuing, divisional and continuation-in-part applications; any requests for continuing examination, substitutions, reissues, extensions, renewals and reexaminations of any of the foregoing; all inventions and discoveries described in any of the foregoing (collectively, the "*Assigned Patent Assets*"), including any and all past, present and future causes of action and other enforcement actions (including, without limitation, for injunctive remedies and relief) and rights to damages and profits, due or accrued, relating to any of the foregoing, including the right to sue and recover for, and the right to profits and damages, due or accrued, arising out of or in connection with, any and all past, present or future infringements or dilutions.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

ASSIGNOR agrees for itself and its successors, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the ASSIGNEE may reasonably request to effectuate fully this assignment.


**IN WITNESS WHEREOF**, ASSIGNOR has caused this Assignment of Patent Assets to be executed by its duly authorized representative on the date set forth below.

**Assignor: TransSINE Technologies Co. Ltd.**


Signature: 

Printed Name: Piero Carninci

Title: Chief Executive Officer

Witnessed by:  (CHAZUKI TAKAHASHI)


Date: 23 October 2019

Witnessed by:  (CHARSHITA SHARMA)

Date: 23 Oct 2019

The Assignee hereby acknowledges and accepts the foregoing assignment.

**Assignee: TransSINE Therapeutics Limited**

Signature: 

Date: 25 Oct 2019

Printed Name: Michael Jones

Title: CEO

**ATTACHMENT A**

US Application No.	US Patent No.
14/008,186	9,353,370